Company Overview and News

 
Cornerstone OnDemand (CSOD) Q2 2017 Results - Earnings Call Transcript

2017-08-04 seekingalpha
Good day, ladies and gentlemen, and welcome to Cornerstone OnDemand's Second Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.
Upvote Downvote

 
Global Business Process Outsourcing (BPO) - Services

2017-03-23 prnewswire
LONDON, March 23, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Business Process Outsourcing (BPO) in US$ Million by the following Horizontal Segments: Finance & Accounting, Customer Services, HR, KPO, and Procurement. The market is also analyzed by the following End-Use Segments: Manufacturing, Telecommunications & Technology, Banking, Insurance & Finance Services, Retail, and Others.
Upvote Downvote

 
Phoenix Group Holdings - 2016 Annual Results

2017-03-20 londonstockexchange
Phoenix Group, the UK's largest specialist closed life fund consolidator1, today announces a strong set of results for the year ended 31 December 2016.
Upvote Downvote

 
BRIEF-Etienne Du Vignaux joins Sopra Steria as CFO

2016-06-01 reuters
* Etienne Du Vignaux assumes his new role since 1 June 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Upvote Downvote

 
Annual Financial Report

2016-05-25 londonstockexchange
I am delighted to report that the Company produced a net asset value total return of +16.6% for the year ended 31st March 2016, compared with the benchmark total return of +7.2% over the same period. The share price total return for the year was +19.7%, as the discount narrowed over the year. I would like to congratulate our Investment Managers for this excellent performance, which continues the Company's very strong long term performance.
Upvote Downvote

 
Phoenix Group Holdings - 2015 Annual Results

2016-03-23 londonstockexchange
Phoenix Group, the UK's largest specialist closed life fund consolidator, today announces a strong set of results for the year ended 31 December 2015, with cash generation in line with the target range and £205 million of incremental embedded value achieved.
Upvote Downvote

 
SugarCRM Closes Strong 2015 With a Record-Breaking Fourth Quarter

2016-02-24 marketwired
CUPERTINO, CA--(Marketwired - Feb 24, 2016) - SugarCRM Inc., the company that enables businesses to create extraordinary customer relationships with the most innovative, flexible and affordable CRM solution in the market, announced today the closing of a remarkable 2015. Already popular among midsize and small companies, in 2015 the company...
Upvote Downvote

 
Clint Oram, CTO and Co-Founder of SugarCRM, Recognized as 2016 CRN(R) Channel Chief

2016-02-22 marketwired
CUPERTINO, CA--(Marketwired - Feb 22, 2016) - SugarCRM Inc., the company that enables businesses to create extraordinary customer relationships with the most innovative, flexible and affordable CRM solution in the market, announced today that CRN®, a brand of The Channel Company, has named SugarCRM CTO and Co-founder Clint Oram to...
Upvote Downvote

 
MRV Communications Form PRER14A

2015-10-02 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS MRV Communications, Inc. Index Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý   Preliminary Proxy Statement o   Confidential, for Use of the Commission Only (as permitted
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...